News from Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 10, 2015, 07:05 ET Raptor Plans to Advance RP103 in a Registration Study in Huntington's Disease Based on Favorable Treatment Effects at 36 Months in CYST-HD Trial

 Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced 36-month efficacy results from a Phase 2/3 clinical trial evaluating RP103 for the...


May 02, 2013, 11:13 ET Multimedia Now Available: Raptor Pharmaceutical's PROCYSBI(TM) Receives FDA Approval for the Treatment of Nephropathic Cystinosis

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has...


May 01, 2013, 04:31 ET Raptor Pharmaceuticals PROCYSBI™ erhält FDA-Zulassung zur Behandlung von nephropathischer Cystinose

-- Markteinführung in den Vereinigten Staaten zum Ende des 2. Quartals 2013 vorgesehen -- Gemäß dem Darlehensvertrag mit HealthCare Royalty...


Apr 30, 2013, 20:34 ET PROCYSBI ™ de Raptor Pharmaceutical autorisé par la FDA pour le traitement de la cystinose néphropatique

-- Lancement commercial aux États-Unis prévu d'ici la fin du deuxième trimestre 2013 -- L'approbation de la FDA débloque 25 millions de...


Apr 30, 2013, 15:51 ET Raptor Pharmaceutical's PROCYSBI™ Receives FDA Approval for the Treatment of Nephropathic Cystinosis

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has...


Feb 10, 2010, 08:00 ET Raptor Pharmaceutical Corp. to Present Cystinosis Research at Lysosomal Disease Network's 2010 WORLD Symposium

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced the presentation of cystinosis data at the Annual...


Jan 11, 2010, 06:30 ET Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced the publication of results from a Phase 2a clinical...


Dec 23, 2009, 17:02 ET Raptor Pharmaceutical Corp. Announces Closing of $7.5 Million Registered Direct Offering

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced that on December 22, 2009, it completed its registered...


Nov 23, 2009, 06:30 ET Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced results from a Phase 2b clinical trial of its...


Nov 23, 2009, 06:30 ET Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP) today announced the presentation of clinical trial data on NGX426, the...


Nov 04, 2009, 19:05 ET Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference

Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that data from a clinical trial of NGX426, the Company's orally administered...


Oct 27, 2009, 07:00 ET Raptor Pharmaceutical Corp. to Present at the 8th Annual BIO Investor Forum

Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that senior management will present a corporate overview and update at the 8th...


Oct 12, 2009, 06:30 ET Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), announced positive findings from the completed treatment phase...


Oct 01, 2009, 06:30 ET Raptor Pharmaceutical Expands Board of Directors

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the...